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Multidrug resistance is among the most pressing obstacles in cancer treatment today. 
Resistance is thought to arise from the ability of cancer stem cells to efflux therapeutic molecules 
using a collection of membrane proteins called ATP-binding cassette (ABC) transporters. There 
is strong interest in targeting ABC transporters to preserve and improve drug efficacy and reduce 
cancer recurrence. Many studies have been performed in vitro using cultured cell lines, but 
currently there is a lack of simple models in which to study ABC transporters in vivo. As a 
solution, I propose to use the fruit fly Drosophila melanogaster for the study of ABC 
transporters, and specifically the D. melanogaster testis stem cell niche—one of the best-
characterized adult stem cell niches. Stem cells have several traits in common with cancer cells, 
including the ability to divide indefinitely, the ability to give rise to many different kinds of 
daughter cells, and chemoresistance. In invertebrates there is mounting evidence for a role ABC 
transporters play in insecticide resistance, but to date there is no peer-reviewed evidence for 
invertebrate stem cell drug resistance in the literature. Here, I present evidence of cytotoxic drug 
efflux in the germline stem cells of the D. melanogaster testis. This was accomplished by 
feeding the chemotherapy drug doxorubicin to wild type flies for two days and measuring 
fluorescence levels using confocal microscopy. Using enhancer trap lines, I also present ABC 






through RNAi knockdown of several ABC transporters, I present evidence of their contribution 
to germline stem cell drug efflux. I also report unexpected phenotypes in the male germline 
resulting from the knockdown of two ABC transporters, CG32901 and CG3164, which points to 
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ATP-Binding Cassette Transporters, Multidrug Resistance, 
and Cancer Stem Cells 
One of the most pressing obstacles in cancer treatment is the resistance of cancer stem 
cells to conventional chemotherapy drugs [1-4]. In many instances, drugs may eradicate the 
majority of a tumor mass but leave behind the cancer stem cells, ultimately leading to cancer 
recurrence. Multidrug resistance is thought to arise from the ability of cancer stem cells to efflux 
therapeutic molecules using a collection of transmembrane proteins called ATP-binding cassette 
(ABC) transporters. This family of proteins has been implicated not only in cancer drug 
resistance [5], but also in cystic fibrosis [6, 7], and antibiotic resistance [8, 9]. Collectively, the 
ABC transporter family are capable of transporting an extremely wide variety of substrates—
from small inorganic ions to both drugs and polypeptides. The family is divided into seven 
classes or subfamilies (ABCA - ABCG) based on amino acid sequence similarities, but so far 
only subfamilies A, B, C, and G have been implicated in cancer multidrug resistance [10]. The 
unifying feature of all ABC transporters is that they consist of two distinct protein domains: a 
transmembrane domain (TMD) embedded within the cell membrane, and a cytosolic nucleotide 
binding domain (NBD) which binds and hydrolyzes adenosine triphosphate (ATP) to fuel 
substrate transport. Structurally, ABC transporters exist as either full transporters, usually 
containing two TMD and two NBD each, or half transporters with only one TMD and NBD, 
which must form homo- or heterodimers to function [11]. While the ABC transporter family as a
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whole is collectively capable of transporting a wide variety of substrates, most individual ABC 
transporters are specific for one or a few substrates. Such specificity is determined by the 
structure of their TMD. Many ABC transporters have overlapping substrate specificity [12], 
while the specific substrates and functional roles of many ABC transporters remain unknown. 
Cancer multidrug resistance (MDR) is a phenomenon which occurs when cancer cells 
simultaneously become resistant to a host of structurally and functionally unrelated drugs. MDR 
has been observed in a number of different cancers, including acute myelogenous leukemia 
(AML), sarcomas, and breast, ovarian, and lung cancer [13-15]. There are a number of cellular 
mechanisms by which MDR can arise, such as blocking apoptotic pathways or activating DNA 
repair pathways (Figure 1.1), but the mechanism most often encountered is increased efflux by 
ABC transporters [13]. The contribution of ABC transporters to the development of MDR in 
cancer cells has been known for some time. ABCB1 (also known as P-glycoprotein or MDR1), 
first discovered in 1976, was shown to be expressed in drug-resistant mutants of the Chinese 
hamster ovary, or the CHO cell line [16]. Subsequently, numerous ABCB1 small-molecule 
inhibitors were developed in hopes of treating MDR, but not a single one of them became an 
enduring treatment option for patients [17]. Three generations of ABCB1 small-molecule 
inhibitors were tested in dozens of clinical studies throughout the 1980s and 1990s. While there 
were some apparent early successes (such as verapamil to treat lymphoma) [18], these inhibitors 
ultimately failed to prove safe and effective [15, 19]. These and subsequent disappointments led 
to outspoken pessimism regarding the pursuit of future ABC transporter inhibitors [20, 21], and 
ultimately the suppression of further research in this area for some decades [22]. In hindsight, it 
appears that the failure of those early clinical trials was due, at least in part, to their narrow focus 
on just one of the 48 distinct human ABC transporters, ABCB1, as a therapeutic target. This is 
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obviously problematic, because we now understand that many distinct ABC transporters may be 
expressed simultaneously within a single tumor. Today, at least 12 human ABC transporters 
from four subfamilies (ABC-A, ABC-B, ABC-C, and ABC-G) have been implicated in cancer 
MDR, and studies using cultured cancer cell lines have revealed that two proteins other than 
ABCB1 are predominantly responsible for MDR, ABCC1 and ABCG2, neither of which was a 
target in those early clinical trials [13]. Another issue was the lack of appropriate tools, such as 
methods for accurately detecting ABCB1 expression in human cancers (let alone other ABC 




Today there is renewed interest in developing ways to target ABC transporters, and a 
growing body of evidence suggests that such efforts could make both classical chemotherapy 
drugs and small-molecule inhibitors more effective and reduce the rate of cancer recurrence [3, 
4, 22-25]. Currently, however, there is a lack of simple models in which to study ABC 
transporters in vivo. Many of the today’s investigations into cancer stem cell drug resistance are 
Figure 1.1: Cellular mechanisms of multidrug resistance, including increased efflux activity 
conferred by ABC transporters. Borrowed from Gottesman et al., 2002. [15]  
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being performed in vitro using cultured cell lines [23, 26]. While these kinds of experiments 
have proven useful in identifying some resistance-thwarting drugs [27, 28], they are limited in 
their ability to account for the influence of a particular tissue’s microenvironment. Not only are 
cancer cells exposed to various cytokines and growth factors from the surrounding tissue, but 
solid tumors often have areas which are hypoxic, nutrient-deprived, and highly acidified [5]. 
Indeed, hypoxia is even thought to be a biomarker for resistant cancer cells [29]. As such, in 
vitro models that do not take the physiology of these microenvironments into account are 
missing potentially valuable insights [30]. 
A solution to this problem may lie in the idea that chemoresistance is not exclusive to 
cancer cells but appears to be a general stem cell trait. Not all stem cells exhibit chemoresistance 
through elevated efflux activity. Those that do have come to be referred to as “side population” 
cells, first identified by their ability to exclude Hoechst 33342, a blue, fluorescent dye which 
binds to AT-rich regions of DNA [31]. Side population cells have since been identified in a 
variety of tissues (e.g. skin, heart, brain) [32]. Some cancer cells also exhibit this elevated efflux 
ability, and these cells are thought to be capable of both tumor initiation and repopulation [33]. 
In other words, these cells seem to function as cancer stem cells (CSCs). The theory of CSCs is 
now well established in the scientific community [1-4], and there is growing interest in targeting 
CSCs to potentially increase the efficacy of anti-tumor therapies (Figure 1.2). Furthermore, there 
is accumulating evidence that both ABC transporter expression and elevated efflux might be 
general stem cell properties, shared by both CSCs and normal stem cell populations alike [34]. 
(Also see Appendix A for evidence of dye exclusion in normal stem cells). This finding makes 
sense conceptually, as it would be important for stem cells to have a defense mechanism against 
harmful toxins in order to repopulate their respective tissues. Interestingly, it also suggests that 
    
 
        5  
                
 
  
ABC transporter overexpression might be an evolved stem cell defense mechanism that has been 
hijacked for cancer chemoresistance. Given this, it is quite possible that well-established stem 
cell model systems could be used to shed new light on the workings of ABC transporters and 





ATP-Binding Cassette Transporter Expression: 
A General Stem Cell Trait 
The finding that ABC transporters are expressed within some normal stem cell 
populations may present the opportunity to study proteins important to cancer MDR using well-
established in vivo stem cell models. The fate of any stem cell daughter is either renewal of the 
stem cell state or differentiation into a cell type specific to the tissue in which the stem cell 
resides. That is, stem cells daughters either self-renew or differentiate. When germline stem cells 
divide, for example, their progeny either retain the stem cell state or begin to develop into mature 
germ cells, ultimately giving rise to gametes. To make this fateful decision, the stem cell depends 
on signals from its local microenvironment, or niche [35]. These signals might come from nearby 
somatic cells or other stem cells. There is evidence that these local signals suppress 
Figure 1.2: The theory of cancer stem cells posits that some cancer cells have stem-like 
properties enabling them of tumor initiation and repopulation. Targeting cancer stem cells could 
increase the efficacy of chemotherapies and reduce tumor recurrence. Borrowed from Reya et 
al., 2001. [3] 
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differentiation, and that distance away from the niche and its signals allows for differentiation 
[36]. As local signals appear to be instrumental to maintaining the stem cell state, it makes sense 
to study stem cell properties such as efflux ability in the context of these signals, and not isolated 
from them. One of the obstacles to doing so, however, is the complexity of stem cell niches and 
the difficulty of genetic manipulations in mammals. Such complexity makes it difficult to 
identify and genetically manipulate specific cell populations [37], as well as difficult to elucidate 
the precise signaling interactions between cell populations in the niche [38, 39]. Such difficulties 
could be overcome by employing a simpler model organism, such as Drosophila melanogaster. 
The benefits of using D. melanogaster are numerous. They include a short generation 
time, inexpensive maintenance, and a well-developed catalogue of robust genetic tools such as 
the Gal4-UAS system [40-42]. The breadth of both Gal4 lines and UAS reporter lines available 
make this a powerful system for manipulating and studying gene expression in vivo. Moreover, it 
is thought that ~ 65% of disease-causing genes in humans have fly homologs [43], giving them 
significant relevance to biomedical research. One area of research this organism is especially 
well-suited for is stem cell biology. In particular, the D. melanogaster testis stem cell niche 
(Figure 1.3), with its ease of manipulation and imaging and its well-characterized tissue 
architecture, is among the best models for studying adult stem cells in vivo [37, 44]. This niche 
supports two distinct populations of stem cells—germline stem cells and cyst stem cells—both of 
which cluster around a small group of somatic, nondividing cells called the hub. This clustering 
allows the stem cells to be identified by their position within the testis, as the stem cells are 
always found adjacent to the hub, and thus stem cell-specific stains are not necessary for 
identification. Furthermore, stem cells have several traits in common with cancer, including the 
ability to divide indefinitely, the ability to give rise to different kinds of daughter cells in some 
    
 
        7  
                
 
  
cases, and chemoresistance, often through ABC transporter expression and elevated efflux 
activity. Given the similarities between stem cells and cancer, the D. melanogaster testis stem 




Which populations of regular stem cells express ABC transporters? Most of the evidence 
comes from vertebrate stem cell populations. The three ABC transporters most notorious for 
cancer multidrug resistance, ABCB1, ABCC1, and ABCG2 [45], are also expressed within some 
normal hematopoietic stem cell populations [46]. It is thought that these ABC transporters 
protect hematopoietic progenitor and stem cells from potentially harmful xenobiotics. ABCB1 is 
expressed in human CD34+ stem cells [47]. ABCG2 is highly expressed in most (if not all) 
hematopoietic stem cells, including 34+/38- and 34+/KDR+ populations, but expression is largely 
lost as these cells mature [48]. Likewise, ABCC1 is expressed at higher levels in hematopoietic 
Figure 1.3: Conceptual model of the Drosophila melanogaster testis stem cell niche. Two 
distinct kinds of stem cells, germline and cyst, cluster around a small group of somatic cells 
called the hub. Distance away from the hub ultimately leads to differentiation. Borrowed from de 
Matunis et al., 2012. [44] 
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stem cells than in mature blood cells [49]. Other, less notorious ABC transporters are also 
expressed in human 34+/38- hematopoietic stem cells, including several members of subfamilies 
ABCA, ABCB, and ABCC [46]. Interestingly, Abcg2 mRNA has been shown to be expressed 
within side population cells of both murine embryonic stem cells and skeletal muscle, as well as 
its ortholog in rhesus monkey bone marrow, indicating that ABC transporter expression may be a 
highly conserved feature of certain stem cell populations [50]. 
Even though the majority of the evidence for ABC transporter expression in regular stem 
cells is specific to hematopoietic stem cells, there is evidence of ABC transporter expression in 
non-hematopoietic stem cell populations as well. As mentioned above, ABCG2 is thought to be 
expressed in both murine embryonic stem cells and skeletal muscle. Moreover, Tang et al. 
characterized the expression profiles of several non-hematopoietic stem cell types, including 
adipose-derived human mesenchymal stem cells and human embryonic stem cells (HUES1, 
HES2, and HES3), and while they found the overall expression levels of ABC transporters to be 
lower in non-hematopoietic compared to hematopoietic stem cells, they did find similar 
expression profiles in these other stem cell types, as well as specific transporters unique to non-
hematopoietic stem cells [51]. This suggests that stem cells depend not on any single ABC 
transporter, but on collections of transporters unique to their cellular identity, resulting in a kind 
of redundancy thought to both protect stem cell integrity and contribute to the difficulty of 
combating cancer multidrug resistance [51]. Unfortunately, it remains unclear whether many 
populations of tissue-specific adult stem cells express ABC transporters, and there have been few 
definitive studies on the matter. However, using lineage tracing experiments, Fatima et al. were 
able to show that ABCG2 is expressed not only within murine blood stem cells (as is already 
widely known), but also within stem cells of the murine small intestine and testis [52]. ABCG2 
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has also been shown to be highly expressed within human neural stem and progenitor cells [53]. 
Future studies will, in all likelihood, identify ABC transporters expressed in even more adult 
stem cell populations. 
Comparatively less is known about the expression of ABC transporters within 
invertebrate stem cell populations. While it has yet to be shown in the literature whether ABC 
transporters are active within D. melanogaster testis stem cells, there are a number of reasons to 
believe it might be so. First, ABC transporters are found across all three domains of life, from 
bacteria to mammals, including a family of 56 proteins encoded in the D. melanogaster genome 
(Table 1). Second, there is a growing body of evidence that suggests ABC transporter expression 
is a general stem cell trait, shared by both cancer and normal stem cells alike [34, 35], and it 
would make evolutionary sense for stem cells of the germline to have a defensive mechanism 
such as ABC transporters to protect against cytotoxins. Third, previous research has 
demonstrated that D. melanogaster insecticide resistance has coincided with the upregulation of 
genes coding for several ABC transporters, and that knockdown of these genes was able to 
increase drug susceptibility [54-56]. Using the 91-R strain of D. melanogaster, which is highly 
resistant to the insecticide 4,4’-dichlorodiphenyltrichloroethane (DDT), Gellatly et al. showed 
that RNAi knockdown of three ABC transporters (Mdr50, Mdr65, and Mrp1) led to decreased 
resistance, reducing LT50 values by 13%, 12%, and 15% respectively [54]. Similarly, Kim et al. 
induced tolerance to the insecticide Ivermectin in Canton S (wild type) flies and showed that 
such tolerance both correlated with the transcriptional upregulation of three ABC transporters 
(Mrp1, CG1824, and CG3327) and was reduced following RNAi knockdown of these 
transporters. Finally, Denecke et al. used CRISPR-Cas9 knockouts to investigate the contribution 
of Mdr49, Mdr50, and Mdr65 in resistance to a variety of insecticides, with knockout mutants 
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showing increased susceptibility to 1, 3, and 5 insecticides, respectively [56]. Interestingly, they 
also found that treatment with verapamil (an ABC transporter-inhibitor) was able to inhibit 
resistance only in flies with at least one function copy of Mdr65, further implicating the 
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Note. *Only top human orthologues with a FlyBase protein alignment score of 8 out of 15 or 
higher were included (corresponding to hits from at least 8 different tools or algorithms used by 




Table 1.1, (Continued) 
 









































































































































While evidence supporting the role ABC transporters play in insecticide resistance is 
mounting, the only direct evidence of invertebrate stem cell drug resistance to date (to the best of 
my knowledge) comes from Dayton et al. [57]. In their BioRxiv preprint, they provided the first 
evidence of ABC transporter expression within the intestinal stem cells (ISC) and enteroblast 
(EB) progenitors of the D. melanogaster midgut. By feeding flies two cytotoxic drugs 
(bortezomib and actinomycin D), dissecting their intestines, and evaluating cell response, they 
showed that ISC and EB exhibit increased drug tolerance relative to mature enterocytes. Then, 
by feeding flies fluorescent dyes and using RNAi to knockdown 55 of the 56 ABC transporters 
in the D. melanogaster genome, they showed that ISC and EB have elevated efflux ability 
conferred by seven ABC transporters (CG1494, CG1819, Mdr50, ABCB7, MRP, CG32091, and 
CG5853). Next, they used enhancer trap lines to characterize the expression patterns of ABC 
transporters in ISCs and EBs relative to mature enterocytes, and found that two of the seven 
previously identified ABC transporters, ABCB7 and CG32091, were specific to ISC and EB cell 
populations. Finally, they found that RNAi knockdown of these two ABC transporters was 
sufficient to restore drug susceptibility to ISCs and EBs.  
All of this evidence taken together led to the question of whether ABC transporters play a 
role in drug efflux and resistance in D. melanogaster testis stem cells. Here, I present evidence of 
cytotoxic drug efflux in the germline stem cells of the D. melanogaster testis. This was 
accomplished by feeding doxorubicin to wild type flies for two days and measuring fluorescence 
levels using confocal microscopy. Then, using enhancer trap lines, I also present ABC 
transporter expression evidence in both the germline and cyst lineages of the testis. Finally, 
through RNAi knockdown of several ABC transporters, I present evidence of their contribution 





resulting from the knockdown of two ABC transporters, CG32901 and CG3164. This work lays 








Drosophila melanogaster Fly Strains 
The Canton S (wild type), Nanos-Gal4, and UAS-GFP fly lines were obtained from Dr. 
Stephen DiNardo, and the c587-Gal4 line from Dr. Erica Matunis. All transgenic fly lines listed 
in Tables 2 and 3 were obtained from the Bloomington Drosophila Stock Centers (BDSC). All of 
the RNAi transgenic lines were created through the joint efforts of the Vienna Drosophila RNAi 
Center, the National Institute of Genetics, and the Drosophila Transgenic RNAi Project (TRiP) at 
Harvard Medical School [58]. The lines were validated by the RNAi Stock Validation and 
Phenotypes Project [58]. All stocks were grown at room temperature and fed on standard fly 
medium. For all fly crosses, resulting F1 progeny were incubated at 29° C for approximately one 
week in order to induce Gal4 expression prior to any further experimental treatment (drug-
feeding, dissection and immunofluorescence staining, etc.).  
Immunofluorescence Staining 
Testis samples were dissected in Drosophila Ringer’s solution, then incubated in 0.5 mL 
of fixative for 20 minutes at room temperature. Fixative solution is 4% formaldehyde and 0.02% 
Triton X-100 diluted in Buffer B (75 mM KCl, 25 mM NaCl, 3.3 mM MgCl2, 16.7 mM KPO4); 
0.5 mL applied per sample. Following fixation, samples were rinsed twice with PBTx (1X PBS, 
0.1% Triton X-100), washed with PBTx, then incubated overnight with 0.5 mL blocking solution 





diluted in blocking solution were applied to samples and incubated overnight at 4°C. Fluorescent 
antibodies were used to visualize the testis niche. Proteins that accumulate in distinct cell 
populations within the testis niche were bound by primary antibodies, which themselves were 
bound by secondary antibodies containing fluorophores (i.e. fluorescent compounds that can be 
visualized upon light excitation). After removing primary antibodies, samples were washed in 
PBTx overnight at 4°C. Secondary antibodies diluted in blocking solution were applied the next 
day and incubated overnight at 4°C. Following secondary antibodies, samples were rinsed in 
PBTx, incubated with Hoechst nuclear stain (if applicable), and washed overnight at 4°C. 
Finally, samples were soaked in a 50% Ringers/50% glycerol solution for at least 30 minutes, 
mounted on microscope slides, and imaged using a Zeiss 700 confocal microscope. A three-
dimensional image of the testis niche was recreated by compiling Z-stacks of 0.5 μm intervals. 
All image analysis was done in ImageJ. 
The hub, germline cells, and cyst lineage cells were stained using mouse anti-fasciclin 3 
antibody (Developmental Studies Hybridoma Bank, 1:50), rabbit or goat anti-vasa antibody 
(Santa Cruz, 1:300), and guinea pig anti-traffic jam (TJ) antibody (1:10,000), respectively [59]. 
Rabbit anti-GFP antibody (Invitrogen, 1:1000) was used to enhance GFP detection in 
experiments involving the UAS-GFP reporter line, and rabbit anti-Cleaved Caspace-3 antibody 
(Asp175) (Cell Signaling Technology, 1:400) was used to detect apoptosis. All secondary 
antibodies were raised in donkey (Jackson ImmunoResearch, 1:400). D. melanogaster testis stem 
cells are identified by their proximity to the hub, and therefore do not require stem-cell specific 
markers. Hoechst 33342 (Invitrogen; 350 nm excitation maximum and 461 nm emission 







To investigate the expression patterns of select ABC transporters, the upstream activating 
sequence (UAS)-GFP reporter line was used. To verify its utility, UAS-GFP flies were first 
crossed to the driver lines Nanos-Gal4 and c587-Gal4, which drive Gal4 expression in the 
germline and cyst lineage, respectively. Following verification, UAS-GFP virgin females were 
crossed to males of each of the Gal4 enhancer trap lines from the BDSC (Table 2). Each of these 
enhancer trap lines have Gal4 insertions near the gene-of-interest, possibly bringing Gal4 
expression under the control of the gene-of-interest’s regulatory sequences. Thus, an ABC 
transporter-Gal4 enhancer trap x UAS-GFP cross may result in the expression of GFP within 
cells where Gal4 is expressed and able to bind UAS, and therefore recapitulate endogenous ABC 
transporter expression. The F1 progeny from each of these crosses were incubated at 29° C for 
approximately one week prior to dissection, immunofluorescence staining, and imaging. 
 
 
Quantifying Efflux in Drosophila melanogaster 
Germline Stem Cells 
To investigate potential drug efflux in the germline stem cells, Canton S flies were fed 
food containing the naturally fluorescent chemotherapeutic, doxorubicin (Thermo Fisher 
Scientific; 470 nm excitation maximum and 585 nm emission maximum). Doxorubicin is an 
intercalating agent that interferes with DNA replication by inhibition of topoisomerase II [60]. It 
FAMILY CG# SYNONYM STOCK # LINE TYPE VENDOR
ABC-B type 3879 Mdr49 24312 Gal 4 Enhancer Trap BDSC
ABC-C type 6214 MRP 77697 Gal 4 Enhancer Trap BDSC
ABC-C type 5772 Sur 25638 Gal 4 Enhancer Trap BDSC
ABC-D type 2316 Abcd1 78384 Gal 4 Enhancer Trap BDSC
ABC-G type 3164 N/A 76211 Gal 4 Enhancer Trap BDSC
ABC-G type 4822 N/A 77564 Gal 4 Enhancer Trap BDSC
ABC-G type 32091 N/A 29892 Gal 4 Enhancer Trap BDSC
ABC-G type 3327 E23 25636 Gal 4 Enhancer Trap BDSC
ABC-H type 11147 N/A 25548 Gal 4 Enhancer Trap BDSC





is also known to induce cell death via the generation of reactive oxygen species (ROS) [61, 62]. 
100 μL of 1 mM doxorubicin were added to fresh vials of perforated fly food and allowed to 
soak overnight. Flies were added the following day and allowed to feed for two days. Flies fed 
on food containing dimethyl sulfoxide (DMSO) served as a negative control. Following feeding, 
testes were dissected in Drosophila Ringer’s solution, fixed, and stained using 
immunofluorescence as previously described. 
Image Analysis and Statistics 
All image analysis was done in ImageJ. Differential efflux activity was measured by 
comparing the fluorescence pixel intensity of doxorubicin in stem cell populations vs. 
differentiating cell populations (i.e. germline stem cells vs. 4- and 8-cell spermatogonia). Rules 
for data analysis were as follows: (1) a minimum of three of each cell type was used per testis; if 
three of each cell type could not be identified, then that testis was not used. (2) All pixel intensity 
measurements were taken with a circular area 2.0 μm in diameter. (3) Pixel intensity 
measurements were taken from the brightest part of each cell (with respect to the x, y, and z 
planes) clearly within the bounds of the cell nucleus. Differences in mean fluorescence pixel 
intensity quantifications between germline stem cells and spermatogonia were tested for 
statistical significance using a two-tailed Paired t-Test in Excel. To do this, intensity 
measurements for both germline stem cells and spermatogonia were averaged within each testis, 
and sample size was determined by the number of testes analyzed. Thus, the Paired t-Test 
compared the mean germline stem cell intensity measurement with the mean spermatogonia 
intensity measurement within each testis. Statistical significance was further verified using a 
pairwise analysis involving nine independent Paired t-Tests in Excel, comparing the first, 





spermatogonia within that same testis. Because the minimum number of testes for any of these 
doxorubicin efflux experiments was twenty (n = 20), this resulted in a minimum of 180 cell-to-
cell pairwise comparisons. 
Ribonucleic Acid Interference or Knockout of 
ATP-Binding Cassette Transporters 
For germline RNAi experiments, the Nanos-Gal4 VP16 driver line was used [63]. This 
driver has expression of the Gal4 protein under control of the nos promoter, which is active in 
both the male and female D. melanogaster germline. Nanos-Gal4 virgin females were crossed 
with males of each of the upstream activating sequence (UAS)-RNAi lines from the BDSC 
(Table 2.2), with the exception of stock #58885, which has a loss-of-function genomic mutation 
in ABCA and thus required no cross. These RNAi lines were designed to express a double-
stranded RNA hairpin loop when UAS binds Gal4, ultimately degrading the mRNA transcript of 
interest. Thus, a Nanos-Gal4 x UAS-RNAi cross results in the expression of dsRNA for RNAi 
only within Nanos-expressing cells (e.g. germline stem cells and progenitors). The F1 progeny 
from each of these Nanos-Gal4 x UAS-RNAi crosses were incubated at 29° C for approximately 
one week prior to doxorubicin feeding and analysis (as previously described). The c587-Gal4 
driver line was used to investigate RNA interference of CG32091 and CG3164 in the cyst 
lineage. To investigate RNA interference of CG32091 and CG3164 in the female germline, 
ovaries from progeny of both Nanos-Gal4 x UAS-RNAi crosses were dissected, stained using 
immunofluorescence, and imaged in the same manner as the testes. Nanos-Gal4 male and female 







FAMILY CG# SYNONYM STOCK # LINE TYPE VENDOR
ABC-A type 1718 ABCA 58885 Mutant KO BDSC
ABC-B type 3879 Mdr49 32405 UAS-RNAi BDSC
ABC-C type 6214 MRP 38316 UAS-RNAi BDSC
ABC-C type 5772 Sur 67246 UAS-RNAi BDSC
ABC-G type 3164 N/A 57478 UAS-RNAi BDSC
ABC-G type 4822 N/A 62475 UAS-RNAi BDSC
ABC-G type 32091 N/A 57783 UAS-RNAi BDSC
ABC-G type 3327 E23 57782 UAS-RNAi BDSC
ABC-H type 11147 N/A 57741 UAS-RNAi BDSC







Investigating Drug Efflux in Germline Stem Cells 
Drug efflux via ABC transporters is a hallmark of resistant cancer cells and stem cells 
alike. In order to investigate drug efflux in D. melanogaster testis germline stem cells (GSCs), 
the drug efflux ability of both GSCs and their differentiating daughter cells (spermatogonia) 
were compared. During spermatogenesis, GSCs undergo asymmetric cell division resulting in 
two daughter cells, one GSC that self-renews to maintain the stem cell state, and a gonialblast 
that exits the niche [37, 44, 64]. Differentiating gonialblasts are enclosed by somatic cyst cells 
and undergo four rounds of transit-amplifying spermatogonial divisions before ultimately giving 
rise to sperm-producing spermatocytes (see Figure 1.3). Because differentiating germline cells 
lose their stem cell characteristics as they move away from the niche, I hypothesized that any 
cytotoxic drug efflux ability of the GSCs would be reduced or lost during differentiation. To test 
this, wild type (Canton S) flies were fed for two days on food soaked in 1 mM doxorubicin. 
Doxorubicin is a common chemotherapeutic used to treat cancer. It is an intercalating agent that 
interferes with DNA replication by inhibition of topoisomerase II [60], and is also known to 
induce cell death via the generation of reactive oxygen species (ROS) [61, 62]. This drug was 
chosen for its natural fluorescence (470 nm excitation maximum, 585 nm emission maximum), 
as it can be readily detected using confocal microscopy. DMSO-fed flies served as a negative 
control (Figure 3.1 F). Following feeding, fly testes were dissected and imaged using 






reaches the testis. The pixel intensity of the doxorubicin stain was then measured using ImageJ in 
both GSCs and differentiating spermatogonia (both 4- and 8-cell spermatogonia were measured), 
and the mean GSC pixel intensity value was compared to the mean spermatogonia pixel intensity 
value within each testis. After analyzing twenty-three testes (n=23), GSCs were found to have, 
on average, lower doxorubicin pixel intensity measurements than differentiating 
spermatogonia (P = 4.4 x 10-7; Figure 3.1 A). The statistical significance of this finding was 
further verified using a pairwise analysis involving nine independent t-Tests (for each: P < 0.05; 
see methodology for details). This result supports the hypothesis that GSCs have increased 
cytotoxic efflux ability relative to their differentiating daughter cells. While this difference in 
doxorubicin accumulation seems to be modest, in some cases the intensity difference can be 
clearly visualized (Figure 3.1 B). To measure the doxorubicin stain in each cell, both the x- and 
y-planes were varied, as well as the z-plane (Figure 3.1 C-D), in an attempt to locate the brightest 
part of each cell (i.e., the area of highest doxorubicin accumulation). As an additional negative 
control, pixel intensity was also measured in the channel used to visualize the Vasa germline 
stain. As expected, this did not result in any significant difference between the GSCs and 































































Figure 3.1: Quantifying cytotoxic drug efflux in GSCs and differentiating spermatogonia. 
(A) Bar graph representing the mean pixel intensity of the doxorubicin stain for both GSCs and 
spermatogonia. Three of each cell type was measured per testis, and sample size (n) was 
determined by the number of testes analyzed. Error bars represent standard error of the mean. 
Statistical significance was determined using a two-tailed Paired t-Test in Excel. (B) Maximum 
intensity projection showing reduced doxorubicin accumulation in GSCs compared to 
differentiating spermatogonia. White and red arrowheads point to GSCs and spermatogonia, 
respectively. (C-D) Pixel intensity of the doxorubicin stain was measured using a circular area 
2.0 μm in diameter and by varying the x-, y-, and z-planes. Here the intensity measurements can 
be seen to increase between z=4 and z=6, representing a 1 μm movement. (E) Representative 
testis from a wild type (Canton S) fly fed 1mM Doxorubicin for two days. (F) Representative 
negative control testis from a wild type fly fed DMSO for two days showing background staining 
in the doxorubicin channel. (G) Bar graph representing the mean pixel intensity of the Vasa 
channel showing no significant difference between GSCs and spermatogonia. (H) Example of 





Selection of ATP-Binding Cassette Transporter 
Gene Candidates 
           Following the observation that GSCs exhibit cytotoxic drug efflux, the next aim was to 
determine whether such efflux was due to ABC transporter activity. In order to identify potential 
gene candidates from the 56 ABC transporters encoded in the D. melanogaster genome, RNA-
seq and microarray expression data from four separate studies were consulted [65-68]. Gan et al. 
analyzed the mRNA profiles of both wild type and bag of marbles (bam) mutant testes (which 
are enriched with undifferentiated stem-like cells) in order to investigate differential gene 
expression [65]. This data allows for the identification of genes with potential significance to the 
testis stem cell populations. Similarly, Terry et al. carried out microarray analyses in testes 
genetically manipulated to be enriched for both cyst stem cell and GSC populations [66]. In 
another, more recent approach, Shi et al. analyzed the gene expression profiles of the male 
Drosophila germline at several distinct stages of spermatogenesis, including GSCs, gonialblasts, 
the two-, four-, eight-, and sixteen-cell transit amplifying stages of spermatogonia, and early and 
late spermatocytes [67]. Finally, Vedelek et al. analyzed the transcriptomes of distinct regions of 
the testis, including the apical, middle, and basal regions, allowing for the identification of genes 
upregulated in the apical region where the stem cell niche is located [68]. By cross-referencing 
data from these studies with genes previously implicated in D. melanogaster drug resistance 
(Gellatly et al., Kim et al., and Dayton et al., discussed above) [54-57], 10 ABC transporter 












ATP-Binding Cassette Transporter Expression in Cyst 
and Germline Stem Cells 
While a primary objective of this study was to determine whether or not ABC transporter 
activity was behind GSC cytotoxic drug efflux, an even more fundamental question was whether 
or not ABC transporters are expressed in either of the D. melanogaster testis stem cell 
populations. To the best of my knowledge, no one has investigated ABC transporter expression 
patterns in either cyst stem cells or GSCs. To do this, enhancer trap lines were acquired for 9 of 
the 10 ABC transporter gene candidates identified (see Table 2.1).  Each of these lines have Gal4 
insertions near the gene of interest and may have Gal4 expression under the control of ABC 
transporter regulator sequences. Thus, by crossing each of these enhancer trap lines to a UAS-
GFP reporter line, it is possible to recapitulate endogenous ABC transporter expression. First, the 
integrity of the UAS-GFP reporter line was tested by crossing it to two separate Gal4 driver 
lines: Nanos-Gal4, which drives Gal4 expression in the germline, and c587-Gal4, which drives 
Gal4 expression in the cyst lineage (Figure 3.2). As expected, this resulted in GFP staining 
patterns consistent with cells positive for Vasa, a germline-specific marker (Figure 3.2 A), and 
cells positive for Tj, a marker of early cyst cells (Figure 3.2 B). Next, the UAS-GFP reporter line 
FAMILY CG# SYNONYM mRNA EXPRESSION DRUG RESISTANCE
ABC-A type 1718 ABCA [65, 67, 68]
ABC-B type 3879 Mdr49 [65, 67] [56]
ABC-C type 6214 MRP [68] [54, 55, 57]
ABC-C type 5772 Sur [65, 67]
ABC-D type 2316 Abcd1 [65, 68]
ABC-G type 3164 N/A [65, 67]
ABC-G type 4822 N/A [65, 66, 67]
ABC-G type 32091 N/A [65] [57]
ABC-G type 3327 E23 [65, 67] [55]
ABC-H type 11147 N/A [65, 67]
Table 3.1: Selection of ABC transporter gene candidates. Genes selected through reported 
mRNA transcript evidence and drug resistance for enhancer trap, RNA interference, and/or 





was crossed to each of the ABC transporter enhancer trap lines, and the GFP expression patterns 
of the F1 testes were analyzed (Figure 3.3 A-I). The results of these enhancer trap experiments 
are summarized in Table 3.2. In general, GFP expression fell into four categories: cyst stem cells 
and somatic cyst cells only (ABCD); somatic cyst cells only (CG11147); cyst stem cells, somatic 
cyst cells, and spermatogonia, but not within GSCs (CG3164); and all four cell types, including 
cyst stem cells, somatic cyst cells, GSCs, and spermatogonia (CG4822, CG32091, E23, Mdr49, 
MRP, SUR). 
Figure 3.2: Positive controls for enhancer trap experiments. (A) Representative testis from 
Nanos-Gal4 x UAS-GFP cross showing GFP expression in a pattern consistent with the Vasa 
germline stain. (B) Representative testis from c587-Gal4 x UAS-GFP cross showing GFP 
expression in a pattern consistent with the Tj cyst lineage stain. All stains (Vasa, GFP, and Tj) 



















These results seem to support the hypothesis that ABC transporters are expressed in D. 
melanogaster testis stem cells and their progenitors. However, a high degree of background 
staining may call into question the validity of these results. While negative controls involving 
only secondary antibodies did not reveal concerning levels of background staining in the stem 
cell niche (Figure 3.4 A-B), the results do seem to be confounded by the use of an anti-GFP 
GENE GSC CySC Germ CYST
ABCD X X
CG3164 X X X
CG4822 X X X X
CG11147 X
CG32091 X X X X
E23 X X X X
Mdr49 X X X X
MRP X X X X
SUR X X X X
Figure 3.3: ABC transporter expression patterns in the Drosophila melanogaster testis niche. 
(A-I) Representative testes from each Gal4-ABC Transporter x UAS-GFP crosses. White and red 
arrowheads point to GSCs and spermatogonia or spermatocytes, respectively, while white and 
red arrows point to cyst stem cells and cyst cells, respectively. GSCs were identified by their 
adjacency to the hub, and cyst stem cells were identified as such if within two GSCs from the 
hub. All stains (Vasa, GFP, and Tj) shown in grey. Scale bars are 20 μm. Stem cell hubs marked 
by asterisks (*). 
Table 3.2: Summary of gene expression patterns in the Drosophila melanogaster testis niche 
from enhancer trap experiments.  
Note. *GSC and CySC stand for Germline Stem Cell and Cyst Stem Cell, respectively. Germ 





primary antibody (Figure 3.4 C-D). Anticipating that the native GFP expression driven by the 
Gal4-UAS system in these enhancer trap experiments might be difficult to detect, an additional 
anti-GFP antibody was used and tagged with a fluorescent secondary antibody, with the intention 
of enhancing the native GFP expression. This indicated that a portion of the experimental GFP 
staining appears to be due not to GFP driven by the Gal4-UAS system, but rather to the non-
specific background staining of the anti-GFP antibody, especially in regions further away from 
the stem cell niche (i.e., the region of the spermatocytes and transit-amplifying spermatogonia). 
In order to differentiate between true experimental GFP staining and this unwanted background, 
repeat experiments should be performed without the anti-GFP antibody. However, there are 
aspects of the experimental GFP staining that cannot be explained by background alone. These 
include staining in the area of the stem cell niche, staining only in the cyst lineage, such as in the 
case of CG11147, and the strong, clean staining observed in the case of MRP, which looks the 
most like the Nanos-GFP and c587-GFP positive controls. Additionally, these results could be 






















Ribonucleic Acid Interference in 
Germline Stem Cells 
In order to determine whether ABC transporter activity was behind GSC cytotoxic drug 
efflux, RNA interference (RNAi) lines were acquired for 8 of the 10 ABC transporter gene 
candidates identified, and a true mutant knockout (KO) line was obtained for ABCA (see Table 
Figure 3.4: Negative controls for enhancer trap experiments. All testis samples from WT Canton 
S flies. (A-B) Representative testes treated with only secondary antibodies. (C-D) Representative 
testes treated with secondary antibodies, as well as Hoechst, anti-GFP, and anti-Fas3. Scale bars 





2.2). Each of these RNAi lines were crossed to a Nanos-Gal4 driver line, resulting in the 
expression of a double-stranded RNA hairpin loop and ultimately the degradation of the ABC 
transporter mRNA transcript within Nanos-expressing cells (i.e., GSCs and their progenitors). 
Surprisingly, germline RNAi knockdown (KD) of two of these ABC transporters resulted in 
extremely abnormal phenotypes in the testis stem cell niche (discussed later). To investigate 
whether the other ABC transporters are required in GSC cytotoxic drug efflux, F1 progeny from 
each of the RNAi crosses were fed doxorubicin before their testes were dissected, imaged, and 
analyzed as previously described. If an ABC transporter is required in GSC drug efflux, then loss 
of that transporter should result in an increased accumulation of doxorubicin in the GSCs, and 
potentially reduce the difference in doxorubicin accumulation between the GSCs and 
spermatogonia. The results of these KD or KO experiments implicated six ABC transporters 
(ABCA, CG4822, CG11147, Mdr49, MRP, and E23) in GSC drug efflux. The loss of each of 
these proteins resulted in no significant difference in the mean doxorubicin pixel intensity 
between GSCs and spermatogonia. The only genotype that was found to maintain a lower 
doxorubicin accumulation in the GSCs relative to spermatogonia was the SUR KD, suggesting 
that the SUR protein does not function in GSC drug efflux. These results suggest a high level 
both of redundancy in export function and overlap in efflux substrate specificity. Experiments 
involving other cytotoxic drugs, double or triple RNAi knockdowns, dominant negative mutants 
(which might be several members of the fly ABC-B subfamily), and treatment with ABC 
inhibitors such as verapamil could help to further illuminate the role these proteins are playing in 









Figure 3.5: Germline RNAi KD or KO of select ABC transporters. (A) Representative testis 
from wildtype control fly (Nanos-Gal4). (B-H) Representative testes from seven germline RNAi 







Figure 3.6: Effect of germline RNAi KD or KO on cytotoxic drug efflux. Sample size (n) was 
determined by the number of testes analyzed per genotype. Error bars represent standard error of 
the mean. Statistical significance was determined using a two-tailed Paired t-Test in Excel. The 
SUR knockdown (KD) was the only genotype found to have a significant difference between 
mean germline stem cell (GSC) pixel intensity and mean spermatogonia pixel intensity. 











Surprisingly, RNAi KD of two ABC transporters, CG32091 and CG3164, resulted in 
total or near total loss of the germline cell lineage (Figure 3.7 A-E). Loss of CG32091 also 
resulted in dramatic expansion of both Tj-positive cyst cells and Fas3-positive hub cells (Figure 
3.7 B-C). It is not clear why loss of these transporters should warrant such extreme phenotypes, 
and naturally such observations inspired a number of new lines of inquiry. First, it was not clear 
whether germline loss was due to increased levels of cell death or increased differentiation and 
movement away from the stem cell niche. To test the hypothesis that loss of CG32091 and 
CG3164 was inducing apoptosis in the germline, testes from both KD genotypes were treated 
with an anti-Cleaved Caspase-3 antibody. While three instances of cell death were observed in 
the Nanos-Gal4 wildtype control testes (n=12), there were no detectable signs of Cleaved 
Caspase-3 dependent apoptosis in either KD testes (Figure 3.7 F-H). This suggests that loss of 
these transporters does not induce Caspase-3 dependent apoptosis. Next, we wondered if this 
phenotype was specific to the germline or whether loss of these transporters might be generally 
cell lethal. To test this, both RNAi lines were crossed to the c587-Gal4 driver line to knockdown 
CG32091 and CG3164 in the cyst lineage. Interestingly, loss of these transporters in the cyst 
lineage resulted in no abnormal phenotype, suggesting a specificity to the germline cell lineage 
(Figure 3.7 I-J). Finally, we wondered if loss of these transporters might also impact the female 
germline. To investigate this, ovaries from CG32091 and CG3164 KD flies were dissected and 
stained using immunofluorescence in the same manner as the testes and imaged with confocal 
microscopy. As with the testes, ovaries from Nanos-Gal4 flies served as a control (Figure 3.7 K). 
Unlike in the testes, KD of these transporters did not result in any apparent loss or disruption of 





transporters, future experiments might repeat these loss-of-function experiments using, for 












Figure 3.7: Germline RNAi KD of CG32091 and CG3164 results in male-specific germline loss. 
(A) Representative testis from wildtype control fly (Nanos-Gal4). (B-C) Germline RNAi of 
CG32091 results in loss or disruption of germline and expansion of both the hub and cyst 
lineages. (D-E) Germline RNAi of CG3164 results in loss of germline. (F) Wildtype (Nanos-
Gal4) testis showing Caspase-3-dependent cell death. (G-H) Germline RNAi of CG32091 and 
CG3164 does not result in detectable Caspase-3-dependent cell death. (I-J) Cyst lineage RNAi 
knockdown of CG32091 and CG3164 does not result in any abnormal phenotype. (K) 
Representative wild type ovary showing germarium and ovarioles. (L-M) Germline RNAi of 
CG32091 and CG3164 does not result in loss or disruption of the female germline. Scale bars are 








The Utility of Drosophila melanogaster in 
Cancer Research 
D. melanogaster has a rich history in biological research. Much of our modern 
understanding of genetics is heavily indebted to the work of fly geneticists of the 20st century 
through to the present. Not only has Drosophila research unveiled many of the fundamentals of 
genetics (including the chromosomal basis of inheritance), but it has also contributed heavily to 
biomedical research, including the discovery of many developmental signaling pathways [38, 
69]. For example, both the Hedgehog pathway and the Notch pathways were first discovered in 
D. melanogaster and were named after their fly mutant phenotypes. Today it is understood that 
misregulations of both pathways are contributors to many diseases including cancer [70], and it 
is thought that abnormal activation of Sonic Hedgehog signaling (which plays a role in the 
regulation of adult stem cell populations) is responsible for the transformation and self-renewal 
of cancer stem cells [71]. Additionally, the Hippo signaling pathway was first discovered in D. 
melanogaster as a regulator of organ size, and later was recognized as an important tumor 
suppressor pathway in humans [72]. In general, the fact that many of the main human signaling 
pathways regulating cell growth are conserved in D. melanogaster, including both oncogenic and 







While the cancer stem cell hypothesis was first derived from studies involving mammals, 
the D. melanogaster stem cell model systems have the potential to shed new light on many 
aspects of cancer stem cells, not the least of which is the question of how cancer stem cells arise 
in the first place. Many models for the origin of cancer stem cells have been proposed. Some 
posit that cancer stem cells arise directly from normal stem cells, possibly by gaining niche-
independence, while others suggest they arise from transit-amplifying progenitor cells [73]. 
While probably there will not be one single answer to this question, and the origin of cancer stem 
cells will likely vary between different types of cancer, researchers are beginning to answer such 
questions with the help of simple model organisms. Using D. melanogaster, Song et al. was able 
to show that cancer stem cells of the brain can arise from transit-amplifying progenitors 
dedifferentiating back into a stem-like state [74]. These in vivo stem cell model systems also 
allow researchers a valuable tool in the effort to find ways to eradicate cancer stem cells without 
harming the tissue-specific stem cell populations crucial to an organism’s health and survival. 
This is another point well illustrated in the work of Song et al., who showed that cancer stem 
cells of the D. melanogaster brain and ovary, because of their dependence on eukaryotic 
translation initiation factor 4E (eIF4E), could be eliminated without harming the tissue-specific 
stem cell populations residing in those locations [74]. Additionally, many tumor models have 
been developed in D. melanogaster, including in areas such as the eye [75], the brain [76], and a 
variety of epithelial tumors which have been used to investigate molecular and cellular 
mechanisms governing tumorigenesis [77]. Moreover, several stem cell tumor models have also 
been developed in D. melanogaster, including an intestinal stem cell model developed by 
Markstein et al., used to screen for novel inhibitors of stem cell-derived tumors [78]., as well as 





the context of selecting ABC transporter gene candidates, but one point not mentioned was that 
their bam mutant testes, which are enriched with undifferentiated stem-like cells, is a stem cell 
tumor model of the testis. Interestingly, when comparing the transcriptional profiles of bam and 
wild type testes, they reported upregulation of over half the ABC transporters encoded in the D. 
melanogaster genome (32/56). Given such a finding, future studies might investigate the role of 
ABC transporters in these D. melanogaster tumor models, and especially those derived from 
stem cells and/or progenitors.  
Evidence of ATP-Binding Cassette Transporter Expression and 
Function in the Drosophila melanogaster 
Testis Stem Cell Niche 
Regarding the current study, the results have potential implications for both cancer and 
developmental biology. Rather than being unique to cancer stem cells, there is mounting 
evidence that ABC transporter expression is a general stem cell trait, and the current study lends 
evidence in favor of that view. Given the significance of ABC transporter activity in both cancer 
multidrug resistance and antibiotic resistance (among other biomedical concerns), there is much 
interest in targeting ABC transporters therapeutically, as well as growing evidence that such 
targeting might prove effective [3, 4, 22-25]. As previously mentioned, D. melanogaster has 
already been established as a model organism for large-scale drug screens [78, 80],  but the 
research proposed here could set the foundation for similar screens using the D. melanogaster 
testis niche to identify, for example, small molecule inhibitors for future combinatorial therapies 
to make conventional chemotherapies more effective. The establishment of the D. melanogaster 
testis niche as a tool for the study of ABC transporters would allow researchers to study these 
proteins in vivo, an ability that is especially important for stem cells which are heavily influenced 





the best understood stem cell niches, it would also be an ideal setting in which to study ABC 
transporter gene expression, many aspects of which are not yet well understood, such as how 
gene expression is regulated between stem cells and their progeny and whether their expression 
is induced by chemotherapeutics (see Appendix B). 
The current work has presented evidence not only of ABC transporter expression in the 
D. melanogaster testis stem cell niche, including stem cells and progenitors of both stem cell 
lineages, (Figure 3.3; Table 3.2) but also evidence of six ABC transporters functioning in GSC 
cytotoxic drug efflux, specifically when exposed to doxorubicin (Figure 3.1; Figure 3.6). While 
the natural fluorescence of doxorubicin makes useful for quantifying efflux, this drug did not 
cause any detectable disruption or stress to the testis architecture, even after longer periods of 
exposure at a ten-fold higher concentration (data not shown). Treatment with other drugs 
(perhaps Actinomycin D or Bortezomib) causing detectable disruption of the testis architecture 
might better illuminate the resistance properties of the germline or cyst stem cells. If such 
resistance were found relative to the surrounding tissue, then the resistance properties of ABC 
transporters could be further investigated. Expanding to other drugs would also make sense in 
the context of ABC transporter substrate specificity. While there is considerable overlap in efflux 
substrates, they are not identical. For instance, doxorubicin is a substrate shared by the three 
most notorious proteins involved in human multidrug resistance, ABCB1, ABCC1, and ABCG2, 
but the ABC inhibitor verapamil is a substrate only of ABCB1 [12]. Experiments with a diverse 
range of drugs could lead to insights regarding the substrate specificities of the D. melanogaster 
ABC transporter family. 
This investigation has focused on just 10 of the ABC transporters encoded in the D. 





investigate the other 46 as well. And while most of the functional RNAi experiments reported 
here focused on the germline, there is no reason not to investigate the role ABC transporters 
might play in the cyst lineage as well. After all, results from the GFP enhancer trap experiments 
suggest that some ABC transporters, such as ABCD and CG11147, are exclusively expressed in 
the cyst lineage and not in the germline (Figure 3.3; Table 3.2). Although there does appear to be 
a discrepancy here, because RNAi KD of CG11147 also resulted in decreased GSC cytotoxic 
drug efflux (Figure 3.6), a result which should not be possible if CG11147 were only expressed 
in the cyst lineage. Further experiments will be needed to address this apparent discrepancy. In 
contrast, other results seem to complement each other nicely. RNAi KD of MRP also decreased 
GSC cytotoxic drug efflux (Figure 3.6), and this finding is consistent with the results of the 
enhancer trap experiments. Of the 10 ABC transporters investigated, MRP had the strongest, 
cleanest staining pattern, with compelling expression evidence in both the germline and cyst 
lineages (Figure 3.3 H). Given such strong expression evidence, it is possible that MRP is also 
playing some functional role in the cyst lineage as well. 
An Unexpected Role for CG32091 and CG3164 
in the Male Germline 
A broader investigation of ABC transporters could also lead to interesting findings not 
only in the context of stem cell drug resistance and cancer, but also in development. Clearly, two 
of the ABC transporters investigated here, CG32091 and CG3164, are playing some previously 
undescribed role in the D. melanogaster testis stem cell niche. Why germline RNAi KD of these 
two transporters leads to total (or near total) loss of the germline is an open question. Since 
germline KD of CG32091 and CG3164 did not result in any detectable cleaved Caspase-3 
(Figure 3.7 F-H), it would seem that loss of these transporters does not induce apoptosis. Perhaps 





GSC homeostasis is being biased toward differentiation instead of self-renewal, ultimately 
leading to loss of the lineage, or perhaps the self-renewal capabilities of the GSCs are being 
compromised altogether. It also seems plausible that loss of these genes is disrupting germline 
enclosure by the cyst cells. Further experiments will be needed to discriminate between these 
possibilities. In whatever case, it is clear that both these KD phenotypes are specific to the male 
germline, as neither cyst lineage KD nor female germline KD resulted in any abnormal 
phenotypes (Figure 3.7 I-M). There is a clear difference, however, between the CG32091 KD 
phenotype and the CG3164 KD phenotype. While germline RNAi KD of either gene results in 
germline loss, only RNAi of CG32091 results in dramatic expansion of both the hub and cyst 
lineages (Figure 3.7 B-E). This difference in phenotype might suggest a difference in function as 
well, indicating that in each case the germline is being lost for different reasons. Here again, 
further experimentation is needed. 
Other instances of male germline loss have been reported in the literature. For example, 
Shields et al. illustrated that loss of the chickadee gene (which encodes profilin, a protein 
necessary for actin-polymerization) results in loss of GSCs, most likely due to defects at the 
GSC-hub interface [81]. Similarly, Chen et al. illustrated that gilgamesh, a homologue of casein 
kinase 1-γ, was necessary for GSC maintenance, and that loss of gilgamesh dramatically reduced 
the number of GSCs in the testis niche [82]. Interestingly, studies in yeast have also implicated 
gilgamesh in regulation of membrane transport, but precise details of this have yet to be worked 
out [83]. Other studies have illustrated that GSCs are susceptible to high levels of reactive 
oxygen species (ROS). ROS disrupt GSC homeostasis by favoring differentiation over self-
renewal, ultimately decreasing GSC number, a phenomenon Tan et al. propose is due to changes 





phenotypes of CG32091 and CG3164 KD described here remains unclear. However, 
understanding both the intrinsic and extrinsic vulnerabilities of GSCs may amount to valuable 
clues in the effort to understand these new phenotypes. 
In searching for possibilities, it may be fruitful to consider the known roles played by 
ABC transporters in other tissues, and perhaps especially those not directly relevant to cancer 
multidrug resistance. It may be that ABC transporters of the D. melanogaster testis niche 
function in hormone uptake. In 2018, Okamoto et al. showed that a membrane transporter, which 
they named Ecdysone Importer (Ecl), is responsible for cellular uptake of the steroid hormone 
ecdysone [85]. Ecdysone binds to a nuclear receptor to induce transcription of genes involved in 
insect molting and metamorphosis [86]. While Ecl is a member of the solute carrier organic ion 
(SLCO) superfamily of proteins, previous research demonstrated that the packaging of ecdysone 
into secretory vesicles is facilitated by the ABC transporter, Atet [87]. Enticingly, both Atet and 
the two ABC transporters identified in the current work, CG32091 and CG3164, are members of 
the ABC-G subfamily. This homology might suggest functional similarity as well. Another 
member of the ABC-G subfamily, E23, also functions in hormone regulation. Hock et al. 
illustrated that E23 can behave as a negative regulator of ecdysone, suppressing ecdysone-
mediated gene transcription [88]. Taken together, these studies reveal not only that steroid 
hormones are clearly substrates of ABC transporters, but also that ABC transporters can play 
interesting and varied roles in regulating steroid hormones. Finally, Syed et al. recently found 
that ecdysone has a role in regulating gene expression in D. melanogaster neural stem cells [89]. 
Given the roles other members of the ABC-G subfamily have been found to play in hormone 
transport, this recent finding that ecdysone regulates gene expression in neural stem cells, and the 





similar roles related to hormone transport or regulation for CG32091 and CG3164 in the D. 
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 “Side population” cells were first discovered for their ability to exclude membrane-
permeable dyes through increased efflux [31] , and have since been discovered in a variety of 
tissues including the skin, heart, and brain [32]. Cancer stem cells use this elevated efflux ability 
to attain chemoresistance, and the same has also been found to be true for many normal stem cell 
populations in vertebrates. In their BioRxiv preprint, Dayton et al. [57] have gone on to show 
that the phenomenon of dye exclusion also extends to invertebrate stem cells as well, specifically 
in the intestinal stem cells and enteroblast progenitors of the D. melanogaster gut. All of this 
taken together led to the question of whether such dye exclusion properties would be present in 
the stem cells of the D. melanogaster testis as well. To test this idea, D. melanogaster testes were 
exposed to a variety of membrane- permeable SYTO dyes. SYTO dyes 17 and 59-64 (Table A.1) 


















Because these SYTO dyes were not detectable following feeding, an ex vivo approach 
was used. Wild type (Canton S) testes were dissected in Ringer’s and incubated for 2 hours in a 5  
μM SYTO dye solution in Schneider’s Drosophila Medium. 7 SYTO dyes were used in total 
DYE Excitation (nm) Emission (nm) 
SYTO 17 621 634 
SYTO 59 622 645 
SYTO 60 652 678 
SYTO 61 628 645 
SYTO 62 652 676 
SYTO 63 657 673 
SYTO 64 599 619 







(SYTO 17, 59-64), and testes incubated only in Schneider’s served as a negative control. 
Following incubation, testes were fixed and stained using immunofluorescence as previously 
described. In theory, ABC transporters would still be functional prior to sample fixation and 
capable of efflux.  
The staining patterns of each of the SYTO dyes in the D. melanogaster testis niche can 
be observed in Figure A.1. Each of the SYTO dyes appear to be excluded, to somewhat varying 
degrees, from the nuclei of GSCs and their progenitors. In some cases, most dramatically 
illustrated by SYTO 64, it appears that encystment of the transit-amplifying spermatogonia is 
playing a role in excluding dye from the germline cells. Within germline nuclei, nucleolus 
staining was also present to varying extents, with SYTO 17 and 64 seeming to have the least, 
perhaps suggesting that these two dyes are the most susceptible to efflux. This experiment serves 
as a proof of concept, illustrating the possibility of studying dye exclusion using the D. 
melanogaster testis stem cell niche. This ex vivo approach could naturally be extended to future 
experiments with other dyes, drugs, and flies of varying genotypes. Future experiments with 
these SYTO dyes might also vary dye concentration and incubation time. A natural follow up to 
this experiment would be to investigate the effect of ABC transporter KD or KO on the 


























































Figure A.1: Staining patterns of SYTO dyes 17 and 59-64 in the Drosophila melanogaster testis 
niche using an ex vivo approach. All testis samples came from wild type (Canton S) flies. Scale 







TRANSCRIPTIONAL UPREGULATION OF ATP-BINDING 
CASSETTE TRANSPORTERS FOLLOWING  























Upregulation of ABC transporters upon cytotoxic exposure could be a protective 
mechanism that evolved in order to ensure successful gamete production. Understanding how 
these genes are activated and regulated within the stem cell niche could lead to important 
insights in how they function within the tumor microenvironments. Given that past studies in D. 
melanogaster have reported an upregulation of ABC transporter genes coinciding with cytotoxic 
drug resistance, we hypothesized that cytotoxic drug exposure will result in a transcriptional 
upregulation in the D. melanogaster testis niche. 
To investigate differential RNA expression of four ABC transporters (MRP, E23, Mdr49, 
and CG32091) in the testis stem cell niche following in vivo drug exposure, wild-type flies 
(Canton S) were fed food containing the naturally- fluorescent chemotherapeutic, doxorubicin 
(Thermo Fisher Scientific). 100 μL of 1 mM doxorubicin were added to fresh vials of perforated 
fly food and allowed to soak overnight. Flies were added the following day and allowed to feed 
for three days. Flies fed on food containing dimethyl sulfoxide (DMSO) served as a negative 
control. Following feeding, 200 testes (100 experimental, 100 control) were harvested in 
Drosophila Ringer’s solution, and testis tips (where the stem cell niche resides) were severed 
using sharpened forceps and immediately stored in TRIzol™. Total RNA was extracted using 
TRIzol™ Plus RNA Purification Kit (following Invitrogen user guide protocol for tissue 
samples). Testis samples were collected in 30-minute intervals before being transferred to 0.5 
mL of TRIzol™ Reagent and stored at –20°C. cDNA was synthesized using SuperScript III 
reverse transcriptase (Invitrogen 18080-044). For quantitative PCR, a PowerTrack SYBR Green  
(ThermoFisher) qPCR assay was utilized with a subsequent melt-curve analysis, following the 
manufacturer’s protocols. The melt-curve analysis was used to validate the amplification curves 






on a BioRad CFX384 Touch Real-Time PCR Detection System using the following parameters: 
1 cycle at 95°C for 2 minutes followed by 40 cycles with 95°C for 5 seconds and 60°C for 30 
seconds, and a final cycle of 95°C for 15 seconds prior to the melt curve. The melt curve ramped 
up from 60°C to 92°C in increments of 1.6°C with 1 minute at each temperature. As a positive 
control, a reference gene, Zfh-1, which encodes a zinc finger homeodomain protein known to be 
expressed in the D. melanogaster testis niche, was included [91]. 
 
Name  Forward  Reverse  Product 
Length 







CAGAGCGGTGATGTCGAGTT  CGCCCAGCAGTTACGAGATT  94 bp 
MDR49  
  
TGCATCGGAGTAGGACTTCAG  AGTGTCTGCTTTCGTCTACGG  139 bp 
CG32091  
  
GCGGGATGTATGTGGGTTTC  CCAAAGAACAGACCGCACAG  126 bp 
ZFH1   TGCGGGGTTAATTCGGGAG  GGTCACACTGGTGTTAAAGGG  120 bp 
 
An initial qPCR assay and melt curve analysis was performed using only the ZFh1 
positive control (Figure B.1), resulting in Cq values around 32 and melt peaks around 78°C for 
both control and experimental samples. A subsequent qPCR assay and melt curve analysis using 
all the genes of interest was performed. Results indicated that mRNA transcripts of only one 
gene of interest (MRP) were upregulated following drug exposure (Figure B.2), while the others 
remained unchanged (Mdr49) or appeared to be downregulated (CG32091, E23). Precise Cq 
values and melt peak temperatures for each gene are reported in Tables B.2 and B.3, 
respectively. The matching melt peak temperatures in both the experimental and control indicate 
that the same target gene was amplified in each sample. 



























Figure B.1: Amplification cycles and melt curve peaks for the Zfh1 control. Two melt peaks at 










Figure B.2: Amplification cycles and melt curve peaks for all four genes of interest and Zfh1 
control. Two melt peaks at each distinct temperature confirm that the same gene targets have 
been amplified in both the experimental and control.   
 
 
Table B.2: Cq Values 
 Experimental Control 
MRP  24.57 29.00 
E23 33.11 29.06 
MDR49 32.19 32.48 
CG32091 32.92 32.04 
ZFH1 33.74 32.70 
Note. Cq (quantitative cycle) values which correspond inversely to the amount of cDNA (and 
thus mRNA) present in sample.  
 
 
Table B.3: Melt Curve Peaks 
 Experimental Control 
MRP 80.5°C 80.5°C 
E23 81.0°C 81.5°C 
MDR49 n.a. (approx. 87.0°C) 87.0°C 
CG32091 82.5°C 82.5°C 
ZFH1 78.0°C 78.0°C 
Note. Melt peaks from melt curve analysis of each qPCR sample. The matching melt peak 
temperatures in both the experimental and control indicate that the same target gene was 







Of the genes investigated here, only MRP mRNA was upregulated following doxorubicin 
exposure. This suggests that MRP is the only ABC transporter of those studied whose expression 
levels in the D. melanogaster testis niche is sensitive to doxorubicin exposure. However, it is 
possible that the other three ABC transporters (E23, MDR49, and CG32091), which all appear to 
be transcriptionally expressed (Figure B.2), might be sensitive to cytotoxic compounds other 
than doxorubicin. This is entirely possible, as ABC transporters are known to vary widely in the 
substrates they transport. The results of this study also do not rule out the possibility that 
doxorubicin may be a transportable substrate of these three non-upregulated ABC transporters, 
as each appears to have a baseline level of expression already established. Although an absolute 
qPCR assay would be required to ascertain this level of expression for certain. Replicate 
experiments would be required to statistically validate the results of this study. In the future, the 
assay utilized here could serve to investigate the expression of other genes in the D. 
melanogaster testis niche. It would also be interesting to investigate the mechanism by which 
transcriptional regulation occurs (including the apparent doxorubicin-induced upregulation 
reported here). In cancer cells, expression of ABC transporters is regulated by a number of 
transcription factors, and upregulation can be influenced by components of malignant 
transformation such as P53, APC, and the MAPK/ERK pathway [92]. Comparatively less is 
known about the transcriptional regulation of ABC transporters in stem cells, and this could be 
the subject of interesting future studies. 
 
